Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1993-6-1
pubmed:abstractText
The stereospecificity of rolipram inhibition of particulate cyclic AMP-specific phosphodiesterase (PDE IV) from guinea-pig eosinophils has been investigated. (-)-Rolipram (IC50 = 0.22 +/- 0.08 microM) was 2.5-fold more potent than (+)-rolipram (IC50 = 0.58 +/- 0.05 microM) in inhibiting membrane-bound PDE IV. Solubilization of PDE IV with deoxycholate (0.5%) and NaCl (100 mM) increased rolipram stereospecificity [IC50 (-)-rolipram = 0.020 +/- 0.002 microM; IC50 (+)-rolipram = 0.33 +/- 0.07 microM]. Partial purification of this solubilized PDE IV by DEAE-trisacryl anion-exchange chromatography reduced the enantiomeric potency difference compared with the pre-chromatographed activity, with (-)-rolipram (IC50 = 0.20 +/- 0.02 microM) being only 2.9-fold more potent than (+)-rolipram (IC50 = 0.57 +/- 0.14 microM). Vanadate-glutathione complex (V-GSH) stimulated membrane-bound PDE IV activity and increased the potency of (-)-rolipram (IC50 = 0.014 +/- 0.006 microM) but not (+)-rolipram (IC50 = 0.32 +/- 0.07 microM). In intact eosinophils, (-)-rolipram (EC50 = 0.19 +/- 0.02 microM) was 10-fold more potent than (+)-rolipram (EC50 = 1.87 +/- 0.09 microM) in enhancing isoprenaline (10 microM)-stimulated cyclic AMP accumulation. Strong correlations were demonstrated for displacement of [3H]rolipram binding to brain membranes by several PDE inhibitors and their inhibition of solubilized PDE IV (r = 0.98, P < 0.001, n = 7) and stimulation of cyclic AMP accumulation in intact cells (r = 0.98, P < 0.001, n = 6). Rolipram was a relatively weak inhibitor of partially purified pig aortic PDE IV and only slight stereospecificity was exhibited [IC50 (-)-rolipram = 1.47 +/- 0.09 microM; IC50 (+)-rolipram = 2.73 +/- 0.38 microM]. The results indicate the presence of a partially concealed stereospecific site (Sr) on eosinophil PDE IV possibly similar to the high-affinity rolipram-binding site in brain through which rolipram can potently inhibit enzyme activity. This site, which apparently is not present on partially purified pig aortic PDE IV, is concealed in freshly prepared eosinophil membranes but is exposed by solubilization or V-GSH treatment and is important in regulating intracellular cyclic AMP accumulation in intact cells.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/8387267-1309798, http://linkedlifedata.com/resource/pubmed/commentcorrection/8387267-1321725, http://linkedlifedata.com/resource/pubmed/commentcorrection/8387267-14907713, http://linkedlifedata.com/resource/pubmed/commentcorrection/8387267-1650216, http://linkedlifedata.com/resource/pubmed/commentcorrection/8387267-1651083, http://linkedlifedata.com/resource/pubmed/commentcorrection/8387267-1663250, http://linkedlifedata.com/resource/pubmed/commentcorrection/8387267-1877039, http://linkedlifedata.com/resource/pubmed/commentcorrection/8387267-2154670, http://linkedlifedata.com/resource/pubmed/commentcorrection/8387267-2159198, http://linkedlifedata.com/resource/pubmed/commentcorrection/8387267-2160582, http://linkedlifedata.com/resource/pubmed/commentcorrection/8387267-222125, http://linkedlifedata.com/resource/pubmed/commentcorrection/8387267-2328751, http://linkedlifedata.com/resource/pubmed/commentcorrection/8387267-2392503, http://linkedlifedata.com/resource/pubmed/commentcorrection/8387267-2552074, http://linkedlifedata.com/resource/pubmed/commentcorrection/8387267-2557965, http://linkedlifedata.com/resource/pubmed/commentcorrection/8387267-2839856, http://linkedlifedata.com/resource/pubmed/commentcorrection/8387267-2993388, http://linkedlifedata.com/resource/pubmed/commentcorrection/8387267-3016560, http://linkedlifedata.com/resource/pubmed/commentcorrection/8387267-3019721, http://linkedlifedata.com/resource/pubmed/commentcorrection/8387267-3036066, http://linkedlifedata.com/resource/pubmed/commentcorrection/8387267-6203537, http://linkedlifedata.com/resource/pubmed/commentcorrection/8387267-6302550
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0264-6021
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
291 ( Pt 2)
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
389-95
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase.
pubmed:affiliation
Rhône-Poulenc Rorer Ltd., Dagenham Research Centre, Essex, U.K.
pubmed:publicationType
Journal Article, Comparative Study